Allen Patricia L 4

What Happened Patricia L. Allen, a director of Zenas BioPharma, was granted a derivative award (an option) covering 18,500 underlying shares on June 15, 2026. The Form 4 reports the transaction as an acquisition (code A) with a price reported as $0.00 (the filing lists $0 total value for the grant). This is a grant of an equity-based compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (timely filing).
• Award: derivative grant covering 18,500 shares; price reported $0.00 on the Form 4.
• Vesting: The option vests 100% on June 15, 2027 (one-year cliff), subject to continued service. (Footnote: "The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.")
• Shares owned after transaction: not disclosed in the provided filing excerpt — see the full Form 4 for total holdings.
• Transaction type: A = grant/award of a derivative security (not an immediate sale or cash exercise).

Context This is a stock-option style compensation grant to a director that vests after one year. Because it’s a derivative award that vests in the future, Allen did not receive free-tradable shares on the grant date and did not sell any shares at the time of this filing. Grants to directors are commonly part of retentive/compensation packages and do not by themselves indicate immediate buying or selling pressure.